- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Medicus Pharma to host fireside chat on SkinJect trial results | 3 | Investing.com | ||
| Mi | Medicus Pharma Ltd: Medicus Pharma To Discuss Positive Skinject Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst | 116 | ACCESS Newswire | Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, PA / ACCESS Newswire... ► Artikel lesen | |
| Mo | Medicus Pharma plant Webcast zu Studienergebnissen bei Basalzellkarzinom | 1 | Investing.com Deutsch | ||
| Mo | Medicus Pharma schedules webcast on basal cell carcinoma study | 1 | Investing.com | ||
| Mo | Medicus Pharma Ltd: Medicus Pharma Announces SkinJect Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 | 186 | GlobeNewswire (Europe) | Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16... ► Artikel lesen | |
| 10.03. | Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum | 358 | ACCESS Newswire | Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy PHILADELPHIA, PA / ACCESS Newswire / March 10, 2026 / Medicus... ► Artikel lesen | |
| 09.03. | Medicus Pharma Ltd: Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset | 232 | GlobeNewswire (Europe) | PHILADELPHIA, March 09, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 06.03. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.03. | Medicus Pharma Reports Phase 2 Results For D-MNA Skin Cancer Treatment, Stock Down In Pre-Market | 1 | RTTNews | ||
| 05.03. | Medicus Pharma Stock Swings After Skin Cancer Treatment Results | 2 | Benzinga.com | ||
| 05.03. | Medicus Pharma Ltd: Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200µg Cohort | 829 | GlobeNewswire (Europe) | PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 28.02. | New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd., CitroTech, Vivos Therapeutics, Inc., and Virtuix Holdings on Bloomberg Television Tonight at 6:30 PM EST | 598 | ACCESS Newswire | The Show Will Also Air Across Latin America and MENA 1230 pm local time. NEW YORK CITY, NEW YORK / ACCESS Newswire / February 28, 2026 / New to The Street will broadcast nationally tonight at 6:30 PM... ► Artikel lesen | |
| 12.02. | Medicus Pharma Ltd: Medicus Pharma on Bloomberg World | 645 | ACCESS Newswire | Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus"... ► Artikel lesen | |
| 10.02. | New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd. | 384 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / February 10, 2026 / New to The Street, the nationally syndicated, long-form television and digital media platform, today announced it has signed a six-part media... ► Artikel lesen | |
| 10.02. | FDA clears Medicus Pharma's prostate cancer drug for phase 2b trial | 4 | Investing.com | ||
| 10.02. | Medicus Pharma Ltd: Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk | 2.661 | GlobeNewswire (Europe) | PHILADELPHIA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical... ► Artikel lesen | |
| 23.01. | Medicus Pharma Ltd: Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony | 958 | ACCESS Newswire | PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing... ► Artikel lesen | |
| 22.01. | Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic and Development Profile | 1 | GlobeNewswire (USA) | ||
| 20.01. | Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 | 2 | GlobeNewswire (USA) | ||
| 05.01. | Medicus Pharma to present phase 2 data at Biotech Showcase 2026 | 2 | Investing.com |
1 2 3 4 Weiter >>
76 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,315 | +0,15 % | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfizer | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfize ► Artikel lesen | |
| GILEAD SCIENCES | 118,32 | -0,12 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| ELI LILLY | 782,30 | -0,29 % | Stammzelltherapien erreichen den Markt - Mesoblast neben Eli Lilly und Novartis im Fokus | ||
| VERTEX PHARMACEUTICALS | 394,50 | +0,38 % | VERTEX PHARMACEUTICALS INC in ruhiger Marktstruktur | ||
| EYEPOINT | 11,290 | 0,00 % | EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug | ||
| LIGAND PHARMACEUTICALS | 177,00 | -0,56 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 156,75 | +0,29 % | Jazz Pharmaceuticals Plc Q4 Profit Climbs | WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) released earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings totaled $203.45 million,... ► Artikel lesen | |
| UNITED THERAPEUTICS | 457,20 | +0,75 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| OPKO HEALTH | 0,999 | +0,95 % | OPKO Health beruft Subbarao V. Uppaluri in den Verwaltungsrat | ||
| ROYALTY PHARMA | 38,800 | -1,05 % | Royalty Pharma plc: Royalty Pharma Announces Expansion of Leadership Team | NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President,... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 19,265 | -2,28 % | CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| BRIDGEBIO PHARMA | 60,14 | +1,38 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| TG THERAPEUTICS | 25,990 | +0,08 % | TG Therapeutics, Inc.: TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million | NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ("TG" or "the Company"), (NASDAQ: TGTX), today announced that it has entered into a new five-year, $750 million senior secured credit... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 7,850 | +4,67 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit | ||
| SOLIGENIX | 1,210 | +1,68 % | SOLIGENIX, INC.: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) | Study results support advancing SGX945 in this difficult-to-treat orphan disease
Results suggest potential durability of response for maintenance therapy
PRINCETON, N.J., Dec. 18... ► Artikel lesen |
MEDICUS PHARMA LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,003 (+0,64 %) liegt der Kurs bei 0,502 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.